3-O-Methylquercetin tetraacetateCAS# 1486-69-7 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 1486-69-7 | SDF | Download SDF |
| PubChem ID | 10005544 | Appearance | Yellow powder |
| Formula | C24H20O11 | M.Wt | 484.4 |
| Type of Compound | Flavonoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | [2-acetyloxy-4-(5,7-diacetyloxy-3-methoxy-4-oxochromen-2-yl)phenyl] acetate | ||
| SMILES | CC(=O)OC1=C(C=C(C=C1)C2=C(C(=O)C3=C(C=C(C=C3O2)OC(=O)C)OC(=O)C)OC)OC(=O)C | ||
| Standard InChIKey | IRJPBMYKKVBCHS-UHFFFAOYSA-N | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Quercetin 3-O-methyl ether is a potent phosphodiesterase (PDE)3/4 inhibitor, it has potential for treating asthma against ovalbumin-induced airway hyperresponsiveness . |
| Targets | PDE | IL Receptor | TNF-α |
3-O-Methylquercetin tetraacetate Dilution Calculator
3-O-Methylquercetin tetraacetate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.0644 mL | 10.322 mL | 20.6441 mL | 41.2882 mL | 51.6102 mL |
| 5 mM | 0.4129 mL | 2.0644 mL | 4.1288 mL | 8.2576 mL | 10.322 mL |
| 10 mM | 0.2064 mL | 1.0322 mL | 2.0644 mL | 4.1288 mL | 5.161 mL |
| 50 mM | 0.0413 mL | 0.2064 mL | 0.4129 mL | 0.8258 mL | 1.0322 mL |
| 100 mM | 0.0206 mL | 0.1032 mL | 0.2064 mL | 0.4129 mL | 0.5161 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 3,5-Dihydroxyergosta-7,22-dien-6-one
Catalog No.:BCN1658
CAS No.:14858-07-2
- Pregabalin
Catalog No.:BCN2175
CAS No.:148553-50-8
- GRK2i
Catalog No.:BCC6048
CAS No.:148505-03-7
- MNS
Catalog No.:BCC3943
CAS No.:1485-00-3
- JMV 390-1
Catalog No.:BCC5922
CAS No.:148473-36-3
- L-732,138
Catalog No.:BCC6821
CAS No.:148451-96-1
- Prion Protein 106-126 (human)
Catalog No.:BCC6027
CAS No.:148439-49-0
- (+)-Matairesinol
Catalog No.:BCN7021
CAS No.:148409-36-3
- Docetaxel Trihydrate
Catalog No.:BCC1535
CAS No.:148408-66-6
- Secoisolariciresinol Diglucoside
Catalog No.:BCN1212
CAS No.:148244-82-0
- H-Dap-OH.HCl
Catalog No.:BCC3186
CAS No.:1482-97-9
- UNC 0642
Catalog No.:BCC8014
CAS No.:1481677-78-4
- 3-O-Methylquercetin
Catalog No.:BCN1660
CAS No.:1486-70-0
- Fmoc-Prolinol
Catalog No.:BCC2710
CAS No.:148625-77-8
- GR 127935 hydrochloride
Catalog No.:BCC7081
CAS No.:148642-42-6
- L-733,060 hydrochloride
Catalog No.:BCC5707
CAS No.:148687-76-7
- SB 204070
Catalog No.:BCC5752
CAS No.:148688-01-1
- Tyrphostin AG 879
Catalog No.:BCC4514
CAS No.:148741-30-4
- (R)-2-Methylcysteine HCl
Catalog No.:BCC4017
CAS No.:148766-37-4
- Carboxy-PTIO, potassium salt
Catalog No.:BCC6789
CAS No.:148819-94-7
- Bismuth Subsalicylate
Catalog No.:BCC3739
CAS No.:14882-18-9
- Rutamarin
Catalog No.:BCN7509
CAS No.:14882-94-1
- Ivabradine HCl
Catalog No.:BCC4350
CAS No.:148849-67-6
- YM 511
Catalog No.:BCC6002
CAS No.:148869-05-0
Potent suppressive effects of 3-O-methylquercetin 5,7,3',4'-O-tetraacetate on ovalbumin-induced airway hyperresponsiveness.[Pubmed:17823872]
Planta Med. 2007 Sep;73(11):1156-62.
We investigated the suppressive effects of 3-O-methylquercetin 5,7,3',4'- O-tetraacetate (QMTA), a more-potent phosphodiesterase (PDE)3/4 inhibitor than quercetin 3-O-methyl ether (3-MQ), which has been reported to have the potential for treating asthma, against ovalbumin (OVA)-induced airway hyperresponsiveness (AHR). The IC50 value of QMTA for PDE3 was significantly less than that for PDE4. According to the Lineweaver-Burk analysis, QMTA (1-10 microM) competitively inhibited PDE3 and PDE4 activities. The Ki values were 0.9+/-0.3 (n=5) and 3.9+/-0.5 (n=5) microM, respectively, which significantly differed from each other, suggesting that QMTA has higher affinity for PDE3 than for PDE4. QMTA (3-10 microM) concentration-dependently relaxed the baseline level, and significantly inhibited cumulative OVA (10-100 microg/mL)-induced contractions in isolated sensitized guinea pig trachealis suggesting that QMTA has bronchodilator and inhibiting effects on mast cell degranulation. After the secondary challenge, the AHR was measured in unrestrained OVA-sensitized mice, with nebulized methacholine (MCh, 6.25-50 mg/mL), by barometric plethysmography using a whole-body plethysmograph. In the present results, QMTA (3-10 micromol/kg, I. P.) dose-dependently attenuated the enhanced pause (Penh) value induced by MCh (25-50 mg/mL). QMTA (3-10 micromol/kg, I. P.) also significantly inhibited total inflammatory cells, macrophages, neutrophils, lymphocytes, and eosinophils in BALF after determination of Penh values. It also significantly suppressed the release of interleukin (IL)-2, IL-4, IL-5, IFN-gamma, and TNF-alpha, with the exception that 3 micromol/kg QMTA did not suppress the releases of IL-5. QMTA even at 1 micromol/kg significantly inhibited eosinophils, IL-2, and TNF-alpha. In conclusion, our results strongly suggest that QMTA has greater potential than 3-MQ for the treatment of asthma.
